S. Kshirsagar

发表

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus

Mukul R Jain, R. Bahekar, A. Joharapurkar, 2018, World journal of diabetes.

Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters

Mukul R Jain, R. Bahekar, Dipam N Patel, 2017, Drug Research.

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect

N. Dhanesha, Mukul R Jain, R. Bahekar, 2012, Pharmacological reports : PR.

Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats

Avnish Patel, N. Dhanesha, Mukul R Jain, 2011, Clinical and experimental pharmacology & physiology.

Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress

Mukul R Jain, A. Joharapurkar, V. Patel, 2021, Drug development research.

Inhibition of 11β‐hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice

N. Dhanesha, Mukul R Jain, A. Joharapurkar, 2012, Clinical and experimental pharmacology & physiology.

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.

N. Dhanesha, Mukul R Jain, R. Bahekar, 2013, Canadian journal of physiology and pharmacology.

Exendin‐4 ameliorates diabetic symptoms through activation of glucokinase

N. Dhanesha, Mukul R Jain, R. Bahekar, 2012, Journal of diabetes.

Discovery of Orally Active, Potent, and Selective Benzotriazole‐Based PTP1B Inhibitors

D. Bandyopadhyay, H. Patel, Mukul R Jain, 2011, ChemMedChem.

Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.

Mukul R Jain, R. Bahekar, Dipam N Patel, 2018, Chemico-biological interactions.

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.

Mukul R Jain, R. Bahekar, Dipam N Patel, 2018, Canadian journal of physiology and pharmacology.

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.

B. Srivastava, Mukul R Jain, Brijesh Kumar Srivastava, 2014, Canadian journal of physiology and pharmacology.

Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.

Mukul R Jain, R. Bahekar, Dipam N Patel, 2017, Drug research.

Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.

N. Dhanesha, Mukul R Jain, R. Bahekar, 2013, European journal of pharmacology.

Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.

T. Gandhi, N. Dhanesha, K. Patel, 2013 .

Hepcidin inhibition improves iron homeostasis in ferrous sulfate and LPS treatment model in mice

Mukul R Jain, A. Joharapurkar, V. Patel, 2021, Drug Research.

Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.

Mukul R Jain, R. Bahekar, Dipam N Patel, 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.

Mukul R Jain, R. Bahekar, A. Joharapurkar, 2019, Current molecular pharmacology.

Pharmacological characterization of ZYDPLA1, a novel long‐acting dipeptidyl peptidase‐4 inhibitor

H. Patel, Mukul R Jain, P. Jadav, 2015, Journal of diabetes.

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

A. Joharapurkar, V. Patel, S. Kshirsagar, 2022, Current research in pharmacology and drug discovery.

Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.

Mukul R Jain, R. Bahekar, A. Joharapurkar, 2016, Canadian journal of physiology and pharmacology.

In vivo antidiabetic activity of nimesulide due to inhibition of amino acid transport

Mukul R Jain, A. Joharapurkar, V. Patel, 2021, Basic & clinical pharmacology & toxicology.

Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?– Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model

H. Patel, P. Patel, Nirav Modi, 2017, Drug Research.

Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β-oxidation

Mukul R Jain, A. Joharapurkar, V. Patel, 2021, Toxicology and Applied Pharmacology.

Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19).

Sanjay Kumar, D. Bandyopadhyay, Rajiv Sharma, 2021, Bioorganic & medicinal chemistry letters.

Repurposing dimethyl fumarate for gastric ulcer and ulcerative colitis: evidence of local efficacy without systemic side effect

Mukul R Jain, A. Joharapurkar, V. Patel, 2022, Medicine in Drug Discovery.

Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.

P. Mitra, Bhupendra Mishra, H. Patel, 2009, Bioorganic & medicinal chemistry letters.

Long-acting peptidomimetics based DPP-IV inhibitors.

Mukul R Jain, P. Jadav, R. Bahekar, 2012, Bioorganic & medicinal chemistry letters.

Pharmacological inhibition of prolyl hydroxylase protects against inflammation‐induced anemia via efficient erythropoiesis and hepcidin downregulation

Mukul R Jain, A. Joharapurkar, V. Patel, 2019, European journal of pharmacology.

Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

A. Joharapurkar, V. Patel, S. Kshirsagar, 2015, Drug Research.

Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia

H. Patel, P. Patel, N. Srinivas, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy.

Mukul R Jain, A. Joharapurkar, V. Patel, 2021, European journal of pharmacology.

Therapeutic potential of coagonists of glucagon and GLP-1.

Mukul R Jain, A. Joharapurkar, V. Patel, 2015, Cardiovascular & hematological agents in medicinal chemistry.

Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice

Mukul R Jain, R. Bahekar, A. Joharapurkar, 2020, Drug Research.

Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.

Mukul R Jain, R. Bahekar, Dipam N Patel, 2018, Cardiovascular & hematological agents in medicinal chemistry.

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase‐4, for the treatment of Type 2 diabetes mellitus

H. Patel, Mukul R Jain, P. Jadav, 2017, British journal of pharmacology.

Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model

Mukul R Jain, R. Bahekar, Dipam N Patel, 2017, Drug Research.

HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases.

A. Joharapurkar, V. Patel, S. Kshirsagar, 2024, Drug research.